Antineutrophil Cytoplasmic Antibody-associated Vasculitis Clinical Trials
3 recruiting trials for Antineutrophil Cytoplasmic Antibody-associated Vasculitis. Eligibility criteria explained in plain English.
TrialFinderData lists 3 Antineutrophil Cytoplasmic Antibody-associated Vasculitis clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 1 / Phase 2 is the largest group at 67% (2 studies); the largest phase groups are Phase 1 / Phase 2: 2, Phase 4: 1.
Research is led by Nkarta, Inc. (1), Marcela V. Maus, M.D.,Ph.D. (1), Amgen (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is NKX019 (drug, 1 trial), followed by Fludarabine, Cyclophosphamide.
Track Antineutrophil Cytoplasmic Antibody-associated Vasculitis trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019...
CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis
The purpose of this study is to evaluate the safety of CC-97540 in relapsed or refractory severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Explore Other Conditions
Frequently Asked Questions
There are currently 3 clinical trials for Antineutrophil Cytoplasmic Antibody-associated Vasculitis, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Antineutrophil Cytoplasmic Antibody-associated Vasculitis, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Antineutrophil Cytoplasmic Antibody-associated Vasculitis, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.